Eli Lilly’s COVID-19 antibody combo already boasts an FDA authorization for patients at a high risk of developing severe disease, but now the company has even stronger data backing the duo.

In trial data released Wednesday, the company said its bamlanivimab-etesevimab duo slashed the risk of hospitalization and death by a whopping 87% versus placebo. Investigators tested a combination of 700 mg of bamlanivimab and 1400 mg of etesevimab in a trial comprising 769 patients total.

It’s the starkest reduction in hospitalizations and deaths for a COVID-19 therapeutic seen so far, and in a “fairly sizable” sample size, Lilly’s COVID-19 therapeutics platform leader Janelle Sabo said in an interview. 

Sponsored By Digital Pharma Europe

Fierce Pharma Marketing is excited to announce the first virtual Digital Pharma Europe!

This summit will profile best-in-class case studies

Read More At Article Source | Article Attribution